The 19th March (here in Australia) will be an interesting day- every opinion I read on google seems to suggest a different option for the company which at least indicates that there are a multitude of opportunities.
I posted a while back the comments published on the FDA newsletter that the pulmonary committee would have been more favourble to PXS if the label was for over 18's only.
Robinson has said that there are "opportunities" to address the concerns raised by the pulmonary committee prior to the FDA decision in March.
I see at worst another shorter trial and data to be reported to FDA. Its certainly not about going back to the beginning.
CRUCIALLY- dont forget that Bronchistasis trail data for 485 subjects is due to be reported in the coming months- that is a very large health issue globally.
I bought some more PXS just before I made this post.
The 19th March (here in Australia) will be an interesting day-...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.3¢ |
Change
-0.001(2.94%) |
Mkt cap ! $39.40M | |||
| Open | High | Low | Value | Volume |
| 3.4¢ | 3.4¢ | 3.2¢ | $46.51K | 1.381M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 186766 | 3.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.4¢ | 196199 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| SNT (ASX) Chart |